A novel coronavirus has been identified as the causative agent of a massive outbreak of atypical pneumonia originating at Wuhan, Hubei province, China. Involved in the formation of the coronavirus replication complex, the viral main protease (M pro , also called 3CL pro ) represents an attractive target for therapy. We determined the crystal structure of the unliganded M pro at 1.75 Å resolution and used this structure to guide optimization of a series of alpha-ketoamide inhibitors.
Introduction
Since December 2019, a new coronavirus has been emerging in the city of Wuhan, the capital of Hubei province in China. Whereas at the beginning of the outbreak, cases were connected to the Huanan seafood and animal market in Wuhan, efficient human-to-human transmission led to exponential growth in the number of cases, with the count standing at >71,000 as of today, with a ~2.4% case-fatality rate. The RNA genome of 2019-nCoV features an identity of about 82% to that of the SARS coronavirus (SARS-CoV); both viruses belong to clade b of the genus Betacoronavirus.
Hence, it has been proposed to rename the new virus as SARS-CoV-2 (Gorbalenya et al., 2020) .
One of the best characterized drug targets among coronaviruses is the main protease (M pro , also called 3CL pro ). Along with the papain-like protease(s), this enzyme is essential for processing the polyproteins that are translated from the viral RNA (Hilgenfeld, 2014) . The M pro operates at no less than 11 cleavage sites on the large polyprotein 1ab (replicase 1ab, ~790 kDa); the recognition sequence at most sites is Leu -Gln¯(Ser,Ala,Gly) (¯ marks the cleavage site). Inhibiting the activity of this enzyme will block viral replication. Since no human proteases with a similar cleavage specificity are known, chances are that inhibitors will exhibit low toxicity.
Here we report the crystal structure of the M pro of 2019-nCoV in the unliganded form and the usage of this structure to design new a-ketoamide inhibitors, compounds 13a and 13b. These compounds were developed on the basis of our first-generation peptidomimetic a-ketoamides, which we designed as broad-spectrum antivirals targeting the M pro s of beta-CoVs and alpha-CoVs, as well as the 3C protease of enteroviruses . Compared to other inhibitors of cysteine proteases, a-ketoamides have the advantage of bearing a relatively mild electrophilic warhead that interacts with the catalytic center of the target enzyme through two hydrogen bonds rather than one, in addition to the covalent bond formed by nucleophilic attack of the catalytic cysteine onto the a-keto moiety.
Results and Discussion
The 1.75-Å crystal structure of the unliganded 2019-nCoV M pro (Fig. 1 ) reveals the high similarity to the SARS-CoV M pro that was to be expected from sequence comparisons (Zhou et al., 2020; Wu et al., 2020) . The r.m.s. deviation between the two free-enzyme structures is 0.53 Å for all Ca positions of the molecule but the isolated domains exhibit r.m.s. deviations of only 0.31 Å (domain II) -0.42 Å (domains I, III) (comparison between the novel coronavirus M pro structure and SARS-CoV M pro , PDB entry 2BX4 (Tan et al., 2005) ). The chymotrypsin-and picornavirus 3C protease-like domains I and II (residues 10-99 and 100-182, respectively) are six-stranded antiparallel b-barrels that harbor the substrate-binding site between them. Domain III (residues 198-303), a globular cluster of five helices, is involved in the regulation of dimer formation of the M pro (Shi & Song, 2006) . 2019-nCoV M pro forms a tight dimer (contact interface, predominantly between domain II of molecule A and the NH2-terminal residues of molecule B ("N-finger"): ~1394 Å 2 ), with the two molecules oriented perpendicular to one another ( Fig. 1 ). Dimerization of the enzyme is necessary for catalytic activity, because the N-finger of each of the two protomers interacts with Glu 166 of the other protomer and thereby helps shape the S1 pocket of the substrate-binding site (Anand et al., 2002) . To reach this interaction site, the N-finger is squeezed in between domains II and III of the parent monomer and domain II of the other monomer. Interestingly, in the SARS-CoV but not in the 2019-nCoV M pro dimer, there is a polar interaction between the two domains III involving a 2.60-Å hydrogen bond between the side-chain hydroxyl groups of residue Thr 285 of each protomer, and supported by a hydrophobic contact between the side-chain of Ile 286 and Thr 285 Cg2.
In 2019-nCoV, the threonine is replaced by alanine (indicated by the black sphere in Fig. 1 ), and the isoleucine by leucine. It has previously been shown that replacing Ser 284 , Thr 285 , and Ile 286 by alanine residues in SARS-CoV M pro leads to a 3.6-fold enhancement of the catalytic activity of the protease, concomitant with a slightly closer packing of the two domains III of the dimer against one another (Lim et al., 2014) . According to that study, this is accompanied by changes of the structural dynamics of the enzyme that transmit the effect of the mutation to the catalytic center. Indeed, the Thr 285 Ala replacement observed in the 2019-nCoV M pro also allows the two domains III to approach each other a little closer (the distance between the Ca atoms of residues 285 in molecules A and B is 6.77 Å in SARS-CoV M pro and 5.21 Å in 2019-nCoV M pro and the distance between the centers of mass of the two domains III shrinks from 33.4 Å to 32.1 Å). Previously, we have designed and synthesized peptidomimetic a-ketoamides as broadspectrum inhibitors of the main proteases of betacoronaviruses and alphacoronaviruses as well as the 3C proteases of enteroviruses . The best of these compounds (11r; see Scheme 1) showed an EC50 of 400 picomolar against MERS-CoV in Huh7 cells as well as low micromolar EC50 values against SARS-CoV and a whole range of enteroviruses in various cell lines.
In order to improve the half-life and the solubility of the compounds in human plasma, and to reduce the binding to plasma proteins, we have modified the compound by hiding the P3 -P2 amide bond within a pyridone ring and by replacing the cinnamoyl group. For a compound related to 11r but modified this way (compound 13a), the half-life in human plasma was increased by 50%, solubility was improved, and plasma protein binding was reduced from 99% to 94%. There was no 7 sign of toxicity in mice. In addition, 13a showed good metabolic stability using mouse and human microsomes, with intrinsic clearance rates Cl int_mouse = 32.00 µL/min/mg protein and Cl int_human = 20.97 µL/min/mg protein. This means that after 30 min, around 80% for mouse and 60% for humans, respectively, of residual compound remained metabolically stable. Pharmacokinetic studies in CD-1 mice using the subcutaneous route at 20 mg/kg showed that 13a stayed in plasma for up to only 4 hrs, but was excreted via urine up to 24 hrs. The Cmax was determined at 334.50 ng/mL and the mean residence time was about 1.59 hrs. Although 13a seemed to be cleared very rapidly from plasma, it was found at 24 hrs at 135 ng/g tissue in the lung and at 52.7 ng/mL in broncheo-alveolar lavage fluid (BALF) suggesting that it was mainly distributed to tissue. In the light of the current CoV outbreak, it is advisable to develop compounds with lung tropism such as 13a. However, compared to 11r, the structural modification led to some loss of inhibitory activity against the main protease of 2019-nCoV (IC50 = 2.39 ± 0.63 uM) as well as the 3C proteases of enteroviruses. To enhance the antiviral activity against betacoronaviruses of clade b (2019-nCoV and SARS-CoV), we sacrificed the goal of broad-spectrum activity including the enteroviruses for the time being and replaced the P2 cyclohexyl moiety of 13a by cyclopropyl in 13b, because the S2 pocket of the betacoronavirus main proteases shows a pronounced plasticity enabling it to adapt to the shape of smaller inhibitor moieties entering this site . Here we present X-ray crystal structures in two different crystal forms, at 1.95 and 2.20 Å resolution, of the complex between aketoamide 13b optimized this way and the M pro of 2019-nCoV (Fig. 2) . One structure is in space group C2, where both protomers of the M pro dimer are bound by crystal symmetry to have identical conformations, the other is in space group P212121, where the two protomers are independent of each other and free to adopt different conformations. Indeed, we find that in the latter crystal structure, the key residue Glu 166 adopts an inactive conformation (as evidenced by its prolonged 8 distance from His 172 and the lack of H-bonding interaction between Glu 166 and the P1 moiety of the inhibitor (see below)), even though compound 13b is bound in the same mode as in molecule A. This phenomenon has also been observed, in a more pronounced form, with the SARS-CoV M pro (Yang et al., 2003) and is consistent with the half-site activity described for this enzyme (Chen et al., 2006) . In all copies of the inhibited 2019-nCoV M pro , the inhibitor binds to the shallow substratebinding site at the surface of each protomer, between domains I and II (Fig. 2) . Through the nucleophilic attack of the catalytic Cys 145 onto the a-keto group of the inhibitor, a thiohemiketal is formed in a reversible reaction. This is clearly reflected in the electron density (Fig. 2) ; the stereochemistry of this chiral moiety is S in all three copies of compound 13b in these structures. The oxyanion (or hydroxyl) group of this thiohemiketal is stabilized by a hydrogen bond from His 41 , whereas the amide oxygen of 13b accepts a hydrogen bond from the main-chain amides of Gly 143 , Cys 145 , and partly Ser 144 , which form the canonical "oxyanion hole" of the cysteine protease. The P1 g-lactam moiety, designed as a glutamine surrogate (Dragovich et al., 1999; Tan et al., 2013) , is deeply embedded in the S1 pocket of the protease, where the lactam amide nitrogen donates a three-center (bifurcated) hydrogen bond to the main-chain oxygen of Phe 140 (3.20/3.10/3.28 Å; values for the structure in space group C2/space group P212121 molecule A/space group P212121 molecule B) and to the Glu 166 carboxylate (3.35/3.33/ -Å), and the carbonyl oxygen accepts a 2.57/2.51/2.81-Å H-bond from the imidazole of His 163 . The P2 cyclopropyl methyl moiety is embraced by the S2 subsite, which has shrunk by 28.4 Å 3 compared to a complex between compound 13a with P2 = cyclohexyl methyl and the SARS-CoV M pro (LLZ et al., unpublished) .
The pyridone in the P3 position of the inhibitor occupies the space normally filled by the substrate's main chain, its carbonyl oxygen accepts a 2.89/2.99/3.00-Å hydrogen bond from the main-chain amide of residue Glu166. Further, the P3 amide donates a 2.83/2.96/2.87-Å H-bond to the mainchain oxygen of Glu 166 . Embedded within the pyridone, the P2 nitrogen can no longer donate a hydrogen bond to the protein; however, our previous crystal structures showed that the P2 mainchain amide of the linear a-ketoamides does not make a hydrogen bond with the protein in all cases, so this interaction does not seem to be essential . The Boc group does not occupy the canonical S4 site of the protease, but is located near Pro 168 (at a distance of 3.81/4.17/3.65 Å); due to this interaction, the latter residue is "pushed" by >2 Å (compared to the structure of the free enzyme). This contact explains that removing the Boc group weakens the inhibitory potency of this compound by a factor of about 2. Interestingly, there is a space between the pyridone ring of 13b, the main chain of residue Thr 190 , and the side-chain of Gln 189 , which is filled by a DMSO molecule in the C2 crystal structure and a water molecule in the P212121 structure.
This suggests that P3 moieties more bulky than pyridone may be accepted here.
Compound 13b inhibits the purified recombinant 2019-nCoV M pro with IC50 = 0.67 ± 0.18 µM. The corresponding IC50 values for inhibition of the SARS-CoV M pro and the MERS-CoV M pro are 0.9 ± 0.29 µM and 0.58 ± 0.22 µM, respectively. In a SARS-CoV replicon (Kusov et al., 2015) , RNA replication is inhibited with EC50 = 1.75 ± 0.25 µM. In human Calu3 cells infected with MERS-CoV, the compound showed excellent antiviral activity (Lucie Sauerhering & Stephan Becker personal communication).
As the next steps in the development of compound 13b towards a potential drug targeting 2019-nCoV or other coronaviruses, we will undertake tests in virus-infected cell cultures and in a small-animal model (once it will become available for 2019-nCoV). Meanwhile, our crystal structures may be used by others for virtual screening and de-novo design of inhibitors.
